Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease

Clinical Biochemistry

Volumn 41, Issue 16-17, 2008, Pages 1362-1367

  Lin, Mao Shin ^a   Li, Hung Yuan ^a,b   Wei, Jung Nan ^c   Lin, Cheng Hsin ^d   Smith, David J ^e   Vainio, Jani ^e   Shih, Shyang Rong ^a   Chen, Ying Hui ^a   Lin, Lung Chun ^a   Kao, Hsien Li ^a   Chuang, Lee Ming ^a,b,f   Chen, Ming Fong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e Biotie Therapies Corp   (Finland)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Amine oxidase; Chronic kidney disease; Microalbuminuria; SSAO; Vascular adhesion protein 1

Indexed keywords

ALBUMIN; CREATININE; VASCULAR ADHESION PROTEIN 1;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; FEMALE; FLUOROMETRY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; URINALYSIS;

ADULT; ALBUMINURIA; AMINE OXIDASE (COPPER-CONTAINING); CELL ADHESION MOLECULES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 55049096363     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.06.019     Document Type: Article

References (37)

1. USRDS 2000 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2000
2. Chronic Kidney Disease: Evaluation, Classification, and Stratification. www.kidney.org/professionals/kdoqi/guidelines.cfm. 2007
3. Salmi M., and Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257 (1992) 1407-1409
4. Salmi M., Tohka S., Berg E.L., Butcher E.C., and Jalkanen S. Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes. J. Exp. Med. 186 (1997) 589-600
5. Smith D.J., Salmi M., Bono P., Hellman J., Leu T., and Jalkanen S. Cloning of vascular adhesion protein-1 reveals a novel multifunctional adhesion molecule. J. Exp. Med. 188 (1998) 17-27
6. Salmi M., Stolen C., Jousilahti P., et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am. J. Pathol. 161 (2002) 2255-2262
7. Boomsma F., van den Meiracker A.H., Winkle S., et al. Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulin-dependent), in Type II (non-insulin-dependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis. Diabetologia 42 (1999) 233-237
8. Meszaros Z., Szombathy T., Raimondi L., Karadi I., Romics L., and Magyar K. Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48 (1999) 113-117
9. Garpenstrand H., Ekblom J., Backlund L.B., Oreland L., and Rosenqvist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in type 2 diabetes mellitus complicated by retinopathy. Diabet. Med. 16 (1999) 514-521
10. Boomsma F., Derkx F.H., van den Meiracker A.H., Man in 't Veld A.J., and Schalekamp M.A. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin. Sc. 88 (1995) 675-679
11. Garpenstrand H., Ekblom J., Bäcklund L.B., Oreland L., and Rosenqvist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabet. Med. 16 (1999) 514-521
12. Mészáros Z., Szombathy T., Raimondi L., Karádi I., Romics L., and Magyar K. Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with BMI and serum triglyceride. Metabolism 48 (1999) 113-117
13. Boomsma F., van Veldhuisen D.J., de Kam P.J., et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc. Res. 33 (1997) 387-391
14. Stolen C.M., Madanat R., Marti L., et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J. 18 (2004) 702-704
15. Yu P.H., Wang M., Deng Y.L., Fan H., and Shira-Bock L. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet. Diabetologia 45 (2002) 1255-1262
16. Boomsma F., Bhaggoe U.M., van der Houwen A.M., and van den Meiracker A.H. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim. Biophys. Acta 1647 (2003) 48-54
17. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
18. American Diabetes Association clinical practice recommendations 2001. Diabetes Care 24 Suppl 1 (2001) S1-S133
19. Levey A.S., Greene T., Kusek J., Beck G.J., and Group M.S. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J. Am. Soc. Nephrol. 11 (2000) 0828A
20. Bolt H.M. Experimental toxicology of formaldehyde. J. Cancer Res. Clin. Oncol. 13 (1987) 305-309
21. Heck H.D., Casanova M., and Starr T.B. Formaldehyde toxicity-new understanding. Crit. Rev. Toxicol. 20 (1990) 397-426
22. Yu P.H., and Zuo D.M. Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis 120 (1996) 189-197
23. Baliga R., Ueda N., Walker P.D., and Shah S.V. Oxidant mechanism in toxic acute renal failure. Drug Metab. Rev. 31 (1999) 971-997
24. Shah S.V. Role of iron in progressive renal disease. Am. J. Kidney Dis. 37 Suppl2 (2001) S30-S33
25. Klahr S. Nephrology forum: obstructive nephropathy. Kidney Int. 54 (1998) 286-300
26. Kitamura M., and Ishikawa Y. Oxidant-induced apoptosis of glomerular cells: intracellular signalling and its intervention by bioflavonoid. Kidney Int. 56 (1999) 1223-1229
27. Hahn S., Krieg Jr. R.J., Hisano S., et al. Vitamin E suppresses oxidative stress and glomerulosclerosis in rat remnant kidney. Pediatr. Nephrol. 13 (1999) 195-198
28. Fiorillo C., Oliviero C., Rizzuti G., Nediani C., Pacini A., and Nassi P. Oxidative stress and antioxidant defenses in renal patients receiving regular haemodialysis. Clin. Chem. Lab. Med. 36 (1998) 149-153
29. Handelman G.J., Walter M.F., Adhikarla R., et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 59 (2001) 1960-1966
30. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., Capeillère-Blandin C., et al. Advanced products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161 (1998) 2524-2532
31. Yilmaz M.I., Saglam M., Caglar K., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am. J. Kidney Dis. 47 (2006) 42-50
32. Dounousi E., Papavasiliou E., Makedou A., et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 48 (2006) 752-760
33. Baba S., Watanabe Y., Gejyo F., and Arakwa M. High-performance liquid chromatographic determination of serum aliphatic amines in chronic renal failure. Clin. Chim. Acta 136 (1984) 49-56
34. Yu P.H., and Dyck R.F. Impairment of methylamine clearance in uremic patients and its nephropathological implications. Clin. Nephrol. 49 (1998) 299-302
35. Jones J.D., and Burnett P.C. Creatinine metabolism and toxicity. Kidney Int 7 (1975) S294-S298
36. Yu P.H., and Deng Y.L. Potential cytotoxic effect of chronic administration of creatine, a nutrition supplement to augment athletic performance. Med. Hypotheses 54 726-8 (1999)
37. Yu P.H., and Zuo D.M. Methylamine, a potential endogenous toxin for vascular tissues: formation of formaldehyde via enzymatic deamination and the cytotoxic effects on endothelial cells. Diabetes 42 (1993) 594-603